VedaBio is building a next-generation molecular detection platform that uses CRISPR technology without the need for target amplification, enabling fast, accurate, and accessible diagnostics. The company positions its system to fill key gaps in patient care by supporting decentralized and point-of-care testing workflows. Recent partnerships, including an agreement with Mammoth Biosciences for expanded CRISPR access and a strategic collaboration with Siemens Healthineers, validate the technical foundation and commercial potential of its platform. Management highlights a highly experienced team drawn from the molecular diagnostics industry to accelerate product development and regulatory pathways. Although still pre-commercial, VedaBio has strengthened its balance sheet through new capital commitments totaling up to $25 million. These funds are earmarked for advancing its CRISPR-based product pipeline toward clinical readiness. The company is headquartered in San Diego and is focused on redefining how clinical diagnostics are delivered in healthcare settings worldwide.

Total raised

$65M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2025